Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Breast Neoplasms 8Waldenstrom Macroglobulinemia 3Rectal Neoplasms 3Lymphoma, Follicular 3Lymphoma, B-Cell, Marginal Zone 3Colorectal Neoplasms 3Colonic Neoplasms 3Triple Negative Breast Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Prostatic Neoplasms 2Pancreatic Neoplasms 2Neuroblastoma 2Neoplasms 2Multiple Myeloma 2Lymphoma, Non-Hodgkin 2Lymphoma, Mantle-Cell 2Lymphoma, Large-Cell, Anaplastic 2Leukemia, Lymphocytic, Chronic, B-Cell 2Intraocular Lymphoma 2Hodgkin Disease 2Fatigue 2Fallopian Tube Neoplasms 2Carcinoma, Ovarian Epithelial 2Breast Neoplasms, Male 2Wilms Tumor 1Unspecified Childhood Solid Tumor, Protocol Specific 1Thromboembolism 1Stomach Neoplasms 1Skin Abnormalities 1Sezary Syndrome 1

Interventions

Docetaxel 292Prednisone 240enzalutamide 193Leuprolide 185Radiotherapy 179Abiraterone Acetate 169Magnetic Resonance Spectroscopy 163bicalutamide 141Goserelin 138Androgen Antagonists 121acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 108Radiosurgery 108apalutamide 92gallium 68 PSMA-11 81abiraterone 81Specimen Handling 73darolutamide 65Surveys and Questionnaires 64Gonadotropin-Releasing Hormone 63Triptorelin Pamoate 58Radiation 57Biopsy 57Brachytherapy 54cabazitaxel 52Standard of Care 51Radiotherapy, Intensity-Modulated 51Zoledronic Acid 50pembrolizumab 49luprolide acetate gel depot 49Flutamide 47

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Prostatic Neoplasms × Enzyme-Linked Immunosorbent Assay × Clear all
NCT01385059 2023-03-07

Axitinib Before Surgery in Treating Patients With High-Risk Prostate Cancer

City of Hope Medical Center

Phase 2 Completed
11 enrolled 10 charts
Genitourinary

Prostatic Neoplasms

NCT01270880 2018-09-18

Hsp90 Inhibitor STA-9090 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy

Barbara Ann Karmanos Cancer Institute

Phase 2 Completed
18 enrolled 8 charts
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡